Jim Hoffman: Could Extracorporeal Removal of NETs Become a ‘Holy Grail’ Therapy Across Multiple Diseases?
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared a post on LinkedIn about a recent article by Michal Santocki and Elzbieta Kolaczkowska, published in Cells:
“Could extracorporeal removal of NETs and other extracellular chromatin outperform many drug treatments with the potential to be a holy grail treatment for multiple diseases and disorders, slowing their progression and aiding recovery, largely free of systemically administered drug-related side effects?
Recent evidence, courtesy of Santersus AG, treating severe Lupus, and backed by over two decades of NETosis research, suggests we should pay much more attention to the universal potential of this therapy to transform disease management, since dysregulated NETosis contributes to the progression of most, if not all, diseases.”
Title: On Neutrophil Extracellular Trap (NET) Removal: What We Know Thus Far and Why So Little
Authors: Michal Santocki, Elzbieta Kolaczkowska
Read the Full Article on Cells.
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 16, 2026, 06:58Rob Maloney: From Past to Progress in Hemophilia Care in the Dominican Republic
-
Apr 16, 2026, 06:51Michael Ertl: Patient-Reported Outcomes Reveal Differences in Perceived Stroke Recovery
-
Apr 16, 2026, 06:40Susan Shea: Real-Time Platelet Function Assessment in Trauma Patients
-
Apr 16, 2026, 06:36Alan Nurden: Structural Complexity of Contact Sites within Platelet Aggregates
-
Apr 16, 2026, 06:29Aaron Rodriguez Calienes: Grateful to Receive 2nd Consecutive DeSousa Award in Stroke and Interventional Research
-
Apr 16, 2026, 06:24Paul Bolaji: A Growing Movement to Transform Stroke Care in Africa
-
Apr 16, 2026, 05:22Cedric Hermans: A Simple Way to Stay Updated in Haemophilia and von Willebrand Disease
-
Apr 16, 2026, 04:29Vijay Shah: Increasing Value of AI-Based Assessment in Cardiovascular Risk Prediction
-
Apr 16, 2026, 04:13Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients